Freenome

We are Freenome, a biotechnology company with a mission to create tools that empower everyone to prevent, detect, and treat their disease, starting with cancer. Since our founding in 2014, we've been driven by the goal of making cancer screening and diagnostics as accurate and accessible as possible. We understand that cancer is a complex and heterogeneous disease, and that's why we're pioneering a comprehensive multiomics platform. This platform combines deep expertise in molecular biology with advanced computational biology, machine learning, and multiple data types to tune into cancer's subtlest cues, even at its earliest and most treatable stages. We believe that no single technology can identify every cancer, so our multimodal approach analyzes genomics, transcriptomics, methylomics, and proteomics to recognize disease-associated patterns among billions of circulating cell-free biomarkers.

Our initial focus is on developing next-generation blood tests for early-stage colorectal cancer and advanced adenomas, with a pipeline of single-cancer and tailored multi-cancer early detection tests under development for other deadly and actionable cancers like lung cancer. We are committed to rigorous clinical programs to drive the discovery, development, and validation of our tests. We're currently in the final stages of enrollment for PREEMPT CRC, our large, prospective registrational study for our colorectal cancer screening test, and have other studies like PROACT LUNG underway. We partner with healthcare organizations, population health decision-makers, pharmaceutical companies, integrated health systems, and academic institutions to integrate our technology and software platform, making cancer detection easier and more accessible for everyone. We're passionate about building a future where a simple, convenient blood draw can empower individuals to access recommended cancer screenings and ultimately save lives. Our team of 'Freenomers' is fueled by this opportunity to make a positive impact on patients' lives, thriving in a culture of respect, cross-collaboration, and innovation.